loading page

Aortic Valve Neocuspidization using glutaraldehyde-treated autologous pericardium: A literature review
  • +3
  • Jeremy Chan,
  • Ayan Basu,
  • Gabriela Di Scenza,
  • Jack bartlett,
  • Ka Siu Fan,
  • Shwe Oo
Jeremy Chan
Bristol Medical School

Corresponding Author:[email protected]

Author Profile
Ayan Basu
St George's University of London
Author Profile
Gabriela Di Scenza
St George's University of London
Author Profile
Jack bartlett
Swansea University Medical School
Author Profile
Ka Siu Fan
University of London
Author Profile
Shwe Oo
Bristol Royal Infirmary
Author Profile


Background: Aortic Valve Neocuspidization using glutaraldehyde-treated autologous pericardium was first performed by Ozaki et al. in 2007. This technique has become an alternative to tissue and mechanical valve as long-term anticoagulation is not required and shows promising midterm results and durability. Method: A comprehensive search was performed on the major database using search terms “Ozaki technique” AND “Aortic Valve Neocuspidization” AND “AV Neocuspidization” AND “Autologous pericardium” AND “glutaraldehyde-treated autologous pericardium”. Articles up to 1st of August 2020 were included in this study. Results: A total of 9 studies with a total of 1342 patients were included. The mean age was 67.36 and 54.23% were male. 66.32% and 23.92% of patients had aortic stenosis and aortic regurgitation, respectively. 66% of patients had a native tricuspid aortic valve and 31.37 % patients’ native aortic valve was bicuspid. Three studies reported their experience performing Aortic Valve Neocuspidization via mini sternotomy. Conclusion: Aortic Valve Neocuspidization is an alternative to biological and mechanical prostheses for surgical aortic valve replacement. The short and mid-term outcome are comparable without the need for long term oral anticoagulation. Long term follow-up data is required for this novel approach to be widely adopted.